Basic Information
LncRNA/CircRNA Name | LINC01355 |
Synonyms | NA |
Region | GRCh38_1:23281309-23286752 |
Ensemble | ENSG00000261326 |
Refseq | NR_110616 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | Drug | |||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | breast cancer |
ICD-0-3 | C50 |
Methods | qPCR, Western blot, RIP |
Sample | MCF10A cells, MCF7 and MDA-MB-231, breast cancer tissue samples and adjacent noncancerous breast tissues |
Expression Pattern | down-regulated |
Function Description | LINC01355 were downregulated in breast cancer cells relative to non-malignant breast epithelial cells. Overexpression of LINC01355 significantly inhibited proliferation, colony formation, and tumorigenesis of breast cancer cells. LINC01355 arrested breast cancer cells at the G0/G1 phase by repressing CCND1. Moreover, LINC01355 interacted with and stabilized FOXO3 protein, leading to transcriptional repression of CCND1. Importantly, LINC01355-mediated suppression of breast cancer growth was reversed by knockdown of FOXO3 or overexpression of CCND1. Clinically, LINC01355 was downregulated in breast cancer specimens and correlated with more aggressive features. There was a negative correlation between LINC01355 and CCND1 expression in breast cancer samples. LINC01355 acts as a tumor suppressor in breast cancer, which is ascribed to enhancement of FOXO3-mediated transcriptional repression of CCND1. |
Pubmed ID | 31243265 |
Year | 2019 |
Title | LINC01355 suppresses breast cancer growth through FOXO3-mediated transcriptional repression of CCND1 |
External Links
Links for LINC01355 | GenBank HGNC NONCODE |
Links for breast cancer | OMIM COSMIC |